BPTH
vs
S&P 500
BPTH
S&P 500
Over the past 12 months, BPTH has underperformed S&P 500, delivering a return of -92% compared to the S&P 500's +12% growth.
Stocks Performance
BPTH vs S&P 500
Performance Gap
BPTH vs S&P 500
Performance By Year
BPTH vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Bio Path Holdings Inc
Glance View
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The company utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein. Its modified product named prexigebersen-A, is its fourth drug candidate.
